Free Access
Issue
J Extra Corpor Technol
Volume 53, Number 1, March 2021
Page(s) 68 - 74
DOI https://doi.org/10.1051/ject/202153068
Published online 15 March 2021
  1. Watt K, Li JS, Benjamin DK Jr, et al. . Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. J Cardiovasc Pharmacol. 2011;58:126–32. [CrossRef] [PubMed] [Google Scholar]
  2. Ramesh Iyer V. Drug therapy considerations in arrhythmias in children. Indian Pacing Electrophysiol J. 2008;8:202–10. [PubMed] [Google Scholar]
  3. Kendrick JG, Macready JJ, Kissoon N. Amiodarone treatment of junctional ectopic tachycardia in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother. 2006;40:1872–5. [CrossRef] [PubMed] [Google Scholar]
  4. Dzierba AL, Abrams D, Brodie D. Medicating patients during extracorporeal membrane oxygenation: The evidence is building. Crit Care (London, England). 2017;21:66. [CrossRef] [PubMed] [Google Scholar]
  5. Shekar K, Roberts JA, McDonald CI, et al. . Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: Results from an ex vivo study. Crit Care. 2015;19:164. [CrossRef] [PubMed] [Google Scholar]
  6. Sherwin J, Heath T, Watt K. Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: A review of the current literature. Clin Therapeut. 2016;38:1976–94. [CrossRef] [Google Scholar]
  7. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: Implications for drug therapy of neonates. Clin Pharmacokinet. 2003;42:403–17. [CrossRef] [PubMed] [Google Scholar]
  8. Watt KM, Cohen-Wolkowiez M, Williams DC, et al. . Antifungal extraction by the extracorporeal membrane oxygenation circuit. J Extra Corpor Technol. 2017;49:150–9. [PubMed] [Google Scholar]
  9. Wildschut ED, Ahsman MJ, Allegaert K, et al. . Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36:2109–16. [CrossRef] [PubMed] [Google Scholar]
  10. Dallefeld SH, Sherwin J, Zimmerman KO, et al. . Dexmedetomidine extraction by the extracorporeal membrane oxygenation circuit: Results from an in vitro study. Perfusion. 2020;35:209–16. [CrossRef] [PubMed] [Google Scholar]
  11. Harthan AA, Buckley KW, Heger ML, et al. . Medication adsorption into contemporary extracorporeal membrane oxygenator circuits. J Pediatr Pharmacol Therapeut. 2014;19:288–95. [CrossRef] [PubMed] [Google Scholar]
  12. Ahsman MJ, Hanekamp M, Wildschut ED, et al. . Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet. 2010;49:407–19. [CrossRef] [PubMed] [Google Scholar]
  13. Shekar K, Roberts JA, McDonald CI, et al. . Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16:R194. [CrossRef] [PubMed] [Google Scholar]
  14. Lemaitre F, Hasni N, Leprince P, et al. . Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care. 2015;19:40. [CrossRef] [PubMed] [Google Scholar]
  15. Ahsman MJ, Wildschut ED, Tibboel D, et al. . Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2010;54:1734–41. [CrossRef] [PubMed] [Google Scholar]
  16. Mehta NM, Halwick DR, Dodson BL, et al. . Potential drug sequestration during extracorporeal membrane oxygenation: Results from an ex vivo experiment. Intensive Care Med. 2007;33:1018–24. [CrossRef] [PubMed] [Google Scholar]
  17. Wildschut ED, de Hoog M, Ahsman MJ, et al. . Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One. 2010;5:e10938. [CrossRef] [PubMed] [Google Scholar]
  18. van der Vorst MM, Wildschut E, Houmes RJ, et al. . Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation. Crit Care. 2006;10:R168. [CrossRef] [PubMed] [Google Scholar]
  19. Cies JJ, Moore WS 2nd, Giliam N, et al. . Oxygenator impact on ceftolozane and tazobactam in extracorporeal membrane oxygenation circuits. Pediatr Crit Care Med. 2020;21:276–82. [CrossRef] [Google Scholar]
  20. Perry JC, Fenrich AL, Hulse JE, et al. . Pediatric use of intravenous amiodarone: Efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol. 1996;27:1246–50. [CrossRef] [PubMed] [Google Scholar]
  21. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984;9:136–56. [CrossRef] [PubMed] [Google Scholar]
  22. Lalloz MR, Byfield PG, Greenwood RM, et al. . Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J Pharm Pharmacol. 1984;36:366–72. [Google Scholar]
  23. Stäubli M, Bircher J, Galeazzi RL, et al. . Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity. Eur J Clin Pharmacol. 1983;24:485–94. [CrossRef] [PubMed] [Google Scholar]
  24. Dayal D. We urgently need guidelines for managing COVID-19 in children with comorbidities. Acta Paediatr. 2020;109:1497–8. [CrossRef] [PubMed] [Google Scholar]
  25. Juenke JM, Brown PI, McMillin GA, et al. . A rapid procedure for the monitoring of amiodarone and N-desethylamiodarone by HPLC-UV detection. J Anal Toxicol. 2004;28:63–6. [CrossRef] [PubMed] [Google Scholar]
  26. Yamasaki Y, Hayashi T, Nakatani T, et al. . Early experience with low-prime (99 ml) extracorporeal membrane oxygenation support in children. ASAIO J. 2006;52:110–4. [CrossRef] [PubMed] [Google Scholar]
  27. Millar JE, Fanning JP, McDonald CI, et al. . The inflammatory response to extracorporeal membrane oxygenation (ECMO): A review of the pathophysiology. Crit Care. 2016;20:387. [CrossRef] [PubMed] [Google Scholar]
  28. Smith AH, Hardison DC, Worden CR, et al. . Acute renal failure during extracorporeal support in the pediatric cardiac patient. ASAIO J. 2009;55:412–6. [CrossRef] [PubMed] [Google Scholar]
  29. Zwiers AJ, de Wildt SN, Hop WC, et al. . Acute kidney injury is a frequent complication in critically ill neonates receiving extracorporeal membrane oxygenation: A 14-year cohort study. Crit Care. 2013;17:R151. [CrossRef] [PubMed] [Google Scholar]
  30. Dagan O, Klein J, Gruenwald C, et al. . Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit. 1993;15:263–6. [CrossRef] [PubMed] [Google Scholar]
  31. Raffaeli G, Pokorna P, Allegaert K, et al. . Drug disposition and pharmacotherapy in neonatal ECMO: From fragmented data to integrated knowledge. Frontiers in Pediatrics. 2019;7:360. [CrossRef] [PubMed] [Google Scholar]
  32. Preston TJ, Hodge AB, Riley JB, et al. . In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol. 2007;39:234–7. [PubMed] [Google Scholar]
  33. Palmgren JJ, Monkkonen J, Korjamo T, et al. . Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm. 2006;64:369–78. [CrossRef] [PubMed] [Google Scholar]
  34. Unger JK, Kuehlein G, Schroers A, et al. . Adsorption of xenobiotics to plastic tubing incorporated into dynamic in vitro systems used in pharmacological research--limits and progress. Biomaterials. 2001;22:2031–7. [CrossRef] [PubMed] [Google Scholar]
  35. Kawabata K, Sugihara K, Sanoh S, et al. . Photodegradation of pharmaceuticals in the aquatic environment by sunlight and UV-A, -B and -C irradiation. J Toxicol Sci. 2013;38:215–23. [CrossRef] [PubMed] [Google Scholar]
  36. Williams DC, Turi JL, Hornik CP, et al. . Circuit oxygenator contributes to extracorporeal membrane oxygenation-induced hemolysis. ASAIO J. 61:190–5. [Google Scholar]
  37. Preston TJ, Ratliff TM, Gomez D, et al. . Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. J Extra Corpor Technol. 2010;42:199–202. [PubMed] [Google Scholar]
  38. Watt KM, Cohen-Wolkowiez M, Barrett JS, et al. . Physiologically based pharmacokinetic approach to determine dosing on extracorporeal life support: Fluconazole in children on ECMO. CPT Pharmacometrics Syst Pharmacol. 2018;7:629–37. [CrossRef] [PubMed] [Google Scholar]
  39. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45:1013–34. [CrossRef] [PubMed] [Google Scholar]
  40. Zhao P, Zhang L, Grillo JA, et al. . Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89:259–67. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.